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Abstract
NM23 (NDP kinase) modulates the gating of muscarinic K channels by agonists through a mechanism distinct from GTP
regeneration. To better define the function of NM23 in this pathway and to identify sites in NM23 that are important for its
role in muscarinic K channel function, we utilized MDA-MB-435 human breast carcinoma cells that express low levels of
NM23-H1. M2 muscarinic receptors and GIRK1/GIRK4 channel subunits were co-expressed in cells stably transfected with
vector only (control), wild-type NM23-H1, or several NM23-H1 mutants. Lysates from all cell lines tested exhibit
comparable nucleoside diphosphate (NDP) kinase activity. Whole cell patch clamp recordings revealed a substantial
reduction of the acute desensitization of muscarinic K currents in cells overexpressing NM23-H1. The mutants NM23-
H1P96S and NM23-H1S44A resembled wild-type NM23-H1 in their ability to reduce desensitization. In contrast, mutants
NM23-H1S120G and NM23-H1S120A completely abolished the effect of NM23-H1 on desensitization of muscarinic K
currents. Furthermore, NM23-H1S120G potentiated acute desensitization, indicating that this mutant retains the ability to
interact with the muscarinic pathway, but has properties antithetical to those of the wild-type protein. We conclude that
NM23 acts as a suppressor of the processes leading to the desensitization of muscarinic K currents, and that Ser-120 is
essential for its actions. ß 1999 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
In atrial myocytes, m2 muscarinic receptors regu-
late the open probability of a speci¢c type of K
channel via a pertussis toxin-sensitive G protein,
Gk [1,2]. Receptor stimulation by cholinergic ago-
nists promotes GDP-GTP exchange in trimeric Gk,
leading to its dissociation into GK-GTP and GLQ
subunits. The free GLQ subunits trigger channel
opening through direct binding to a G protein-
coupled inwardly rectifying K channel that is a tet-
ramer of two subunits, GIRK1 and GIRK4 [3^5].
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This signaling pathway follows a relatively simple
mechanism, since it is membrane-delimited; never-
theless, as in other G protein-coupled processes, the
¢nal response to the agonist is modulated by other
cell components (for review see [6]). One of these is
NM23/NDP kinase, which we found to be essential
for channel gating by agonists, through an unknown
function that is distinct from in situ GTP regenera-
tion [7].
The NM23 protein family is well conserved
through prokaryotic and eukaryotic evolution. Five
human NM23 family members have been identi¢ed
[8^12], which are thought to function in growth, de-
velopment and di¡erentiation, apoptosis and tumor
metastasis (reviewed in [13^15]). Most NM23s exhib-
it a NDP kinase activity mediated by a phosphohis-
tidine intermediate; other biochemical functions re-
ported for NM23 include serine autophosphorylation
on residues 44 and in a fragment containing residues
120, 122 and 125 [16^19], a histidine protein kinase
activity [20^23], serine protein kinase activity in the
presence of urea [24], kinase activity as a complex
with glyceraldehyde-3-phosphate dehydrogenase
[25], and a potential DNA transactivational activity
[26^28].
The biological functions of NM23 have been ex-
plored in several model systems. Null mutations of
the Drosophila homolog, abnormal wing discs (awd),
cause abnormal cell morphology, aberrant di¡eren-
tiation and cell necrosis in the imaginal discs leading
to lethality post metamorphosis [29,30]. A point mu-
tation in awd changing proline 97 to a serine (P97S)
results in no phenotype, but produces a complex ar-
ray of developmental abnormalities when expressed
in combination with an eye color mutation, prune
(pn) [31], and is therefore referred to as the killer-
of-prune (k-pn) mutation. X-Ray crystallography
studies of NM23 homologs localize P97 to a loop
that contains three of the residues involved in nucleo-
tide binding and also contributes to intersubunit in-
teractions in hexameric NM23s [32^34]. P97 is not
always conserved, and equivalents to the P97S sub-
stitution are found in mitochondrial isoforms of
NM23 from normal tissues [11,35].
In tumor metastasis, reduced NM23 expression
has been correlated with aggressive disease in cohort
studies using several cancer cell types (reviews in [13^
15]). Substitution of the serine 120 residue to glycine
was reported in advanced neuroblastomas, suggest-
ing this as a mechanism of aggressiveness as well [36].
Serine 120 lies near the active site residue involved in
phosphate transfer, H118, and is invariant in all
known NM23s, from bacteria to humans. The
NM23-H1S120G mutant has unusual properties which
may be responsible for its negative e¡ect on IKACh
desensitization. The mutant protein has a folding
defect [37], and forms not only hexamers as does
the wild-type polypeptide, but also lower order
oligomers, in particular dimers [38]. Another impor-
tant feature of the S120G mutant is that this substi-
tution strengthens the interaction between NM23-H1
and a 28 kDa protein which is probably identical to
the Mer5 homolog that co-puri¢es with NM23 from
several tissues [38,39].
Transfection studies have established that NM23
overexpression can reduce the in vivo tumor meta-
static potential of several breast carcinoma or mela-
noma cell lines [40^45]. In vitro studies established
that NM23-H1 overexpression induces morphologi-
cal and biosynthetic evidence of di¡erentiation upon
three-dimensional culture [46], and inhibits tumor
cell motility in Boyden chamber assays in response
to multiple stimulants [47]. Site directed mutagenesis
of NM23-H1 indicated that the k-pn residue (P96 in
human NM23s) and serine 120, but not serine 44, are
critical to motility inhibition [23,48].
The best described model system for the study of
NM23 in vivo is the metastatic human breast carci-
noma line MDA-MB-435. In contrast to cardiac my-
ocytes and cell lines commonly utilized for heterolo-
gous expression of muscarinic K channels, which
contain large amounts of the two major isoforms
of NM23, H1 and H2, MDA-MB-435 cells express
normal amounts of NM23-H2, but are markedly de-
¢cient in NM23-H1 [43,48], the isoform that is often
associated with signal transduction processes. Thus,
transfection of wild-type NM23-H1 into MDA-MB-
435 cultures not only reduces markedly their meta-
static potential but also alters the colonization re-
sponse to TGFL1 [43] and suppresses chemoattrac-
tant (PDGF, IGF1)-stimulated motility [47,48]. In an
e¡ort to de¢ne the role of NM23 in the muscarinic
K channel pathway, we utilized MDA-MB-435 cells
stably transfected with an empty vector or with wild-
type NM23-H1 as a transient expression system for
the muscarinic K channel system. Additionally,
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cells expressing mutated forms of NM23-H1 were
used to identify sites of NM23-H1 that are important
for modulation of muscarinic K channel activity.
This approach allowed us to determine that NM23-
H1 stabilizes muscarinic K channel activity by
blocking desensitization during sustained exposure
to agonists. We also show here that serine 120 is of
critical importance for the regulation of channel
function by NM23-H1.
2. Materials and methods
2.1. Materials
Cell culture and transfection reagents including
G418, LipofectAMINE, and OptiMEM were pur-
chased from Life Technologies. GTP was from Boeh-
ringer Mannheim, and MgWATP was from Sigma. All
other chemicals were of the highest purity available.
Cells were routinely cultured in Dulbecco’s modi¢ed
Eagle’s medium supplemented with 10% newborn
calf serum, 2 mM L-glutamine, 0.1 units/l penicillin,
0.1 mg/l streptomycin and 0.2 g/l G418 at 37‡C in a
humidi¢ed 5% CO2 atmosphere.
Clonal cell lines bearing control and test NM23
constructs are derived from two separate experiments
following similar protocols; the characterization of
these lines, as well as of the puri¢ed recombinant
wild-type and mutant NM23 have been described
previously [43,48]. Brie£y, one set of cell lines [43]
was generated by transfection with pCMV without
an insert (C-100; control cells) or pCMVnm23-H1
expression vector (H1-177, wild type). H1-177 cells
express 8-fold more NM23-H1 protein than C-100
cells. A second group of clonal lines [48] was gener-
ated by side-by-side transfection of MDA-MB-435
cells with pCMV (K10 and K27, controls),
pCMVnm23-H1 (P57 and P62), pCMVnm23-H1S44A
(J20), pCMVnm23-H1P96S (S22), pCMVnm23-
H1S120G (I205 and I108) and pCMVnm23-H1S120A
(R4). The wild-type transfectants (P lines) from this
second experiment express 2.1^4.1-fold more NM23-
H1 than control (K) lines [48]. Expression levels rel-
ative to controls for the other clones are: I108, I205
and R4 clones, 1.6^3.1-fold; J20, 3-fold; S22, at least
4-fold. MDA-MB-435 cells express normal amounts
of NM23-H2 [43,48]; accordingly, lysates from all
cell lines tested here have sizable NDP kinase activity
[48]. More importantly, the puri¢ed recombinant
mutant NM23-H1 proteins have signi¢cant NDP
kinase activity [23,37,38].
2.2. Transient transfection
Cells plated in 35 mm or 12-well dishes were trans-
fected with equal amounts of plasmids encoding
muscarinic m2 receptors (in the pCMV vector [49]),
GIRK1 and GIRK4. GIRK1 [50] was inserted in the
pCDNA3.1/Zeo(+) vector, while GIRK4 (or CIR [4])
was subcloned into the pCDNA3 vector. A reporter
plasmid (pGreen Lantern; Life Technologies) that
encodes a point mutant of the green £uorescent pro-
tein was also present, at 1/5 the concentration of the
other vectors, to allow identi¢cation of transfected
cells by direct £uorescence microscopy. Transfections
were performed using LipofectAMINE (6 Wl/Wg plas-
mid) as recommended by the manufacturer. After
24^72 h, cells were lifted from dishes with PBS-
EDTA, centrifuged and transferred to complete me-
dium bu¡ered with 25 mM HEPES. Results reported
for each of the clonal lines assayed come from 2^5
separate transfections.
2.3. Electrophysiological recording
For whole cell patch clamp recording, the external
(bath) solution contained 140 mM NaCl, 5.4 mM
KCl, 2 mM CaCl2, 1 mM MgCl2, and 10 mM
HEPES, pH 7.4 with NaOH. Acetylcholine (ACh;
1 WM), atropine (1 WM) and BaCl2 (0.5 mM) were
added to the bath solution when indicated. After a
gigaseal was established, cells were lifted and posi-
tioned near the outlet of a rotary valve system to
allow rapid exchange of bath solutions [51].
The surface of MDA-MB-435 cells displays nu-
merous microvilli which often prevent seal forma-
tion; we found that stable, high resistance seals re-
quired the use of patch pipettes made from quartz
glass. Pipettes were ¢lled with a solution containing
140 mM KCl, 2.5 mM ATPcMg, 0.2 mM GTP, 1 mM
EGTA, 0.1 mM CaCl2, 2 mM MgCl2, and 10 mM
HEPES, pH 7.4 with KOH; the resistance was in the
range of 3^7 m6. All experiments were performed at
22^25‡C. Currents were recorded and analyzed as
described [52]. In most experiments the membrane
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potential was held at 340 mV for 0.25 s, and alter-
natively stepped to 3120 mV, 385 mV, 35 mV and
40 mV for 0.25 s. In order to determine the fast
kinetics of activation and deactivation of IKACh, cells
were held at 340 mV. Outward currents were re-
corded while ACh was applied and washed out by
a rapid change in the bath solution, and the activa-
tion and deactivation rates were measured as previ-
ously described [51]. The term ‘muscarinic K cur-
rent’ (IKACh) refers to the di¡erence between the
ACh-induced and the basal current in each cell. Stu-
dent’s t-test was used for analysis of the data, which
are expressed as mean þ S.E.
MDA-MB-435 cells have Ca2-activated K chan-
nels (KCa); when the latter are active, the resulting
currents can overshadow muscarinic K currents.
We found that KCa channels could be eliminated
by thapsigargin, a blocker of the Ca2 pump that
causes depletion of internal Ca2 stores within 1 h
of treatment [53]. Control experiments indicate that
pre-treatment of cells with thapsigargin does not af-
fect the function of heterologously expressed muscar-
inic K channels. Thus, suspended cells were rou-
tinely incubated with 200 nM thapsigargin at 37‡C
for a minimum of 60 min before transfer to the re-
cording chamber.
2.4. Quantitation of desensitization
The extent of acute desensitization (D) of IKACh in
MDA-MB-435 cells during a short (1.1^1.3 min) ex-
posure to ACh was estimated by determining the
di¡erence between the amplitude of the early peak
of the response to agonist, Ipeak; and the IKACh cur-
rent measured after 1 min of exposure to ACh, I1min
(see Fig. 2). This value was then normalized to Ipeak,
the maximal IKACh current in each cell (Eq. 1).
D  Ipeak3I1min=Ipeak 1
To assess the degree of recovery from desensitiza-
tion, ACh was applied twice to each cell with a 5 min
interval between additions, and the peak value of
IKACh was determined for each response. The ratio
of the second Ipeak to the ¢rst (Ipeak2/Ipeak1) was taken
as a measure of the extent to which the system had
recovered from desensitization following the ¢rst
challenge with agonist.
3. Results
3.1. Expression of muscarinic K+ channels in
MDA-MB-435 cells
Fig. 1 shows that transfection of MDA-MB-435
cells with cDNAs for m2 receptors and for the two
subunits of muscarinic K channels, GIRK1 and
GIRK4, generates a macroscopic current with the
essential features of the muscarinic K current of
atrial myocytes, IKACh [54]. Thus, the currents
evoked by ACh reverse at 378 mV, near the equili-
brium potential for potassium ions (384 mV with
our solutions), are blocked by atropine in the pres-
ence of agonist (Fig. 1), and by 0.5 mM extracellular
Ba2 (not shown). Moreover, the expressed muscar-
inic K channel exhibits the characteristic inward
recti¢cation of the native channels, that is, outward
currents recorded at potentials positive to Ek are
smaller than the inward currents measured at hyper-
polarizing potentials (Fig. 1A,C). Additionally, mus-
carinic K currents display the signature relaxation
kinetics of atrial IKACh [55] that result from a gating
process intrinsic to the channel protein [56]. These
are time-dependent changes in current during single
voltage steps, namely an increase at hyperpolarizing
potentials (Fig. 1B) and a decrease at depolarizing
potentials.
Close to half (48.3%) of the transfected cells as-
sayed had detectable basal IKACh currents, that is, a
subpopulation of muscarinic K channels was active
in the absence of agonists. A typical example is
shown in Fig. 1A. Basal IKACh is easily distinguished
from native background currents of MDA-MB-435
cells, which are outwardly rectifying, reverse at po-
tentials between 350 and 0 mV and resist block by
external Ba2 (Fig. 1). Basal currents are a promi-
nent feature of expressed GIRK-type channels
[4,50,57], and seem to originate from agonist-inde-
pendent interaction between channels and endoge-
nous G proteins. Consequently, these currents resist
block by atropine, but are completely blocked by
external Ba2 (Fig. 1).
Although most characteristics of native muscarinic
channels are preserved upon expression in breast
cancer cells, there are signi¢cant di¡erences between
atrial IKACh and the currents expressed in MDA-MB-
435 cells. Namely, the rates at which currents rise
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Fig. 1. Co-expression of m2 muscarinic receptor, GIRK1 and GIRK4 in MDA-MB-435 cells gives rise to muscarinic K currents.
Shown is a recording from a cell overexpressing wild-type NM23-H1 (clone P62), transiently transfected with cDNA encoding the m2
receptor, GIRK1 and GIRK4. (A) Membrane currents were elicited by stepping the voltage periodically to 35 mV (outward currents)
and 3120 mV (inward currents) from a holding potential of 340 mV; voltage steps lasted 0.25 s. The lines represent the current re-
corded at the end of an individual step to the voltages indicated, measured at every 1.5 s and plotted as a function of time. The cell
was bathed in external solution supplemented with ACh (1 WM), ACh and atropine (Atr; both at 1 WM) or BaCl2 (Ba; 0.5 mM) dur-
ing the periods indicated by the bars. At the times indicated by the symbols, current-voltage relationships were measured (see C); b,
no additions; S, ACh; F, ACh+atropine; 8, Ba. (B) Time-dependent changes in currents elicited by a voltage step from 340 mV to
3120 mV and back to 340 mV. Currents were digitized at 1 kHz. Symbols are as in A, and identify the times where traces were ob-
tained. Traces recorded in ACh+atropine and with no additions to the bath are virtually identical ; for the sake of clarity only the lat-
ter are shown. (C) Current-voltage relationships measured at the times indicated in A by the corresponding symbols. Note that values
measured in ACh+atropine (F) and in bath solution with no additions (b) are practically superimposed.
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upon agonist application and disappear following
agonist washout are markedly slower in breast can-
cer cells than in cardiac myocytes. Thus, while rapid
application of agonist activates IKACh in atrial cells at
a rate of 550 min31 [51], in breast cells the activation
rate is 119.5 min31 ( þ 16.3; n = 10), that is, 4.5-fold
slower. The deactivation of IKACh upon agonist is 16-
fold slower in MDA-MB-435 cells (ddeact of 8 s) than
in atrial myocytes (ddeact of 0.5 s). Overexpression of
NM23-H1 or its mutants did not a¡ect the rates of
deactivation and activation of IKACh in any of the
cell lines tested. Slow activation and deactivation of
macroscopic GIRK currents have been observed in
other expression systems, and are proposed to result
from lack of the appropriate isoform of RGS (regu-
lator of G protein signaling) proteins [58,59].
3.2. Overexpression of NM23-H1 attenuates the
desensitization of IKACh
Application of 1 WM ACh to MDA-MB-435 cells
transfected with m2 receptors and GIRK1/GIRK4
Fig. 2. Desensitization of muscarinic K currents is blunted in MDA-MB-435 cells overexpressing NM23-H1. Shown are currents re-
corded from MDA-MB-435 cells transfected with vector alone (low NM23-H1; clone C100), with wild-type NM23-H1 (high NM23-
H1; clone P62) and, for comparison, from a bullfrog atrial myocyte. Conditions were as in Fig. 1, but only outward currents are
shown. Whole cell currents were recorded at the end of 0.25 s pulses from 340 mV to 35 mV (low and high NM23-H1) or from
385 mV to 35 mV (atrial myocyte). The recording from the atrial cell was performed as previously described [52]. Exposure to ACh
took place during the intervals marked by bars; ACh1 and ACh2 are the ¢rst and second applications of agonist to each cell. Also
shown are the amplitude of the early peak of the response to agonist, Ipeak; and the IKACh current measured after 1 min of exposure
to ACh, I1min.
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channel subunits produced peak currents of similar
magnitude in control cells, de¢cient in NM23-H1
(201.7 þ 41.8 pA; n = 22) and in cells overexpressing
NM23-H1 (215.1 þ 32.2 pA; n = 27). This suggests
that the expression levels for channels and receptors
in the two types of cells are comparable. Basal cur-
rents were observed in either type of cell at similar
frequencies (47.9% of control and 53.8% of wild-type
transfectants) and magnitudes. Moreover, analysis of
the voltage dependence of currents, as well as the
kinetics of activation and deactivation of IKACh,
shows no signi¢cant di¡erences between the two
groups of cells. However, overexpression of NM23-
H1 had distinct e¡ects on the desensitization of
IKACh, characterized by a decrease in current ampli-
tude in the continued presence of agonist. As illus-
trated in Fig. 2, when ACh was applied to control
cells, currents ¢rst rose (upward de£ection) to a
peak, and then decayed, with a pro¢le reminiscent
of the time course of ACh-induced currents in atrial
myocytes.
In control cells (transfected with vector only) the
decline in ACh-induced current was such that after
1 min of exposure to agonist, the amplitude of IKACh
currents was reduced markedly relative to the initial
peak response. In contrast, wild-type NM23-H1
transfectants (Figs. 1A and 2) displayed almost no
desensitization. In the cells shown in Fig. 2, after
1 min of exposure to ACh the evoked muscarinic
K currents decayed by 56% in the control cell, while
remaining at 82.6% of the initial value in cells trans-
fected with wild-type NM23-H1. Comparison of the
normalized amplitude of desensitization (see Section
2.4) of muscarinic K currents in control and wild-
type transfected clonal lines originating in two sepa-
rate experiments shows that there is a consistent 2-
fold di¡erence between the two types of cells. Thus,
desensitization in C100 cells (control) reached
48.63% ( þ 6.0; n = 11) of the maximal current in
1 min, while in H1-177 (expressing wild-type NM23-
H1) currents were decreased only by 26.7% ( þ 3.3;
n = 13) in the same period; the di¡erence is statisti-
cally signi¢cant (P6 0.01). The same pattern was
seen with cells generated in another transfection ex-
periment (Fig. 3), where comparison of two control
lines (K10, K27) and two lines transfected with wild-
type NM23-H1 (P57, P62) shows that desensitization
was reduced by a factor of 2.1 by overexpression of
NM23-H1 (P6 0.001). Moreover, within a set of
transfectants, similar degrees of desensitization were
observed in individual clonal lines bearing identical
constructs of NM23-H1 (K, P and I clones; Fig. 3),
establishing the reproducibility of the data.
Note that, as observed by others [58], the slow
activation of IKACh in heterologous expression sys-
tems attenuates the fast desensitization that results
in a sharp initial peak in atrial myocytes (Fig. 2).
Therefore, the magnitude of desensitization of
IKACh in breast cancer cells is most probably under-
estimated, and may in fact exceed the values meas-
ured with native muscarinic K currents. Addition-
ally, because of the overlap between activation and
desensitization in MDA-MB-435 cells, the decay of
IKACh does not follow a simple bi-exponential course
as in cardiac myocytes (reviewed in [6]), where fast
and slow desensitization can be resolved. Given the
complex kinetics of IKACh in our assay system, the
process of desensitization was analyzed without dis-
tinction between fast and slow components.
3.3. Recovery from desensitization
If NM23-H1 a¡ects the processes involved in the
Fig. 3. E¡ect of overexpression of wild-type and mutant
NM23-H1 on the desensitization of IKACh. The bar graph
shows the mean ( þ S.E.) desensitization amplitude of IKACh in
clonal lines deriving from a single side-by-side transfection of
MDA-MB-435 cells with pCMV (K10 and K27, controls),
pCMVnm23-H1 (P57 and P62), pCMVnm23-H1S120G (I205 and
I108), pCMVnm23-H1P96S (S22), pCMVnm23-H1S120A (R4) and
pCMVnm23-H1S44A (J20). Desensitization was assessed as de-
scribed in Section 2.4, following the protocol illustrated in Figs.
2 and 4; (n), number of experiments.
BBAMCR 14445 4-3-99
A.d.S. Otero et al. / Biochimica et Biophysica Acta 1449 (1999) 157^168 163
desensitization of IKACh, then it may also in£uence
the ability of these cells to reverse the changes in-
duced by desensitization. When ACh is applied to
atrial myocytes and washed out after 1 min, a second
exposure to ACh generates currents of comparable
size to the ¢rst response, provided that cells are al-
lowed to recover for at least 5 min between each
challenge with agonist (Fig. 2;[6,52]). To examine
how NM23 a¡ects the recovery of IKACh from desen-
sitization, we utilized a protocol where ACh was ap-
plied twice to a cell, with the two exposures to ago-
nist being separated by a rest period of 5 min. The
relative amplitude of the peak currents obtained was
taken as an estimate of the degree of recovery (see
Section 2.4). As illustrated in Fig. 2, in cells over-
expressing NM23-H1 the currents measured during
both exposures to ACh are of similar amplitude.
Quantitation of the extent of recovery in all wild-
type transfectants tested indicates that the repeat ap-
plication of agonist elicits currents that reach 80%
( þ 0.03%; n = 22) of the magnitude of the ¢rst re-
sponse (Fig. 5). In contrast, a second application of
ACh to control cells elicits currents that are signi¢-
cantly reduced (P6 0.001; Fig. 2), amounting to
only 60% ( þ 0.05%; n = 18) of the magnitude of ¢rst
response. These data suggest that when NM23-H1
levels are low (control cells), resensitization of
IKACh is impaired, while intermediate (cardiac myo-
cytes) and high levels of expression (NM23-H1 trans-
fectants) completely restore the recovery process.
3.4. Mutational analysis of the role of NM23-H1 in
the slow desensitization of IKACh
The above results demonstrate that NM23-H1
neutralizes in part the processes that lead to the de-
Fig. 5. Recovery from desensitization in cells expressing wild-
type and mutant NM23-H1. The bar graph shows the mean
( þ S.E.) recovery from desensitization, determined as described
in Section 2.4. Deterioration of seals during prolonged record-
ing often led to cell death before completion of experiments;
for this reason, values obtained from clonal lines bearing the
same construct of NM23-H1 were pooled. *P6 0.05 and
***P6 0.005%, when compared to WT value (dashed line) ; (n),
number of experiments.
Fig. 4. E¡ect of the S120G and P96S mutations of NM23-H1 on desensitization of muscarinic K currents. The experimental proto-
col and symbols are as in Fig. 2. Results shown are from experiments performed in cells expressing NM23-H1S120G (clone I205) and
NM23-H1P96S (clone S22).
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sensitization of IKACh, but shed no light on how
NM23 accomplishes this task. To identify sites in
NM23-H1 that are important for its e¡ects on desen-
sitization, in the next series of experiments we ex-
pressed IKACh in MDA-MB-435 cells stably trans-
fected with constructs of four point mutants of
NM23H1: S120G (I108 and I205), S120A (R4),
P96S (S22) and S44A (J20). These mutants were pre-
viously tested for their e¡ect on the motility of
MDA-MB-435 cells; while S120G, S120A and P96S
eliminate the motility suppressing activity of NM23-
H1, S44A behaves like wild-type NM23-H1 [48].
Control and wild-type NM23-H1-transfected clonal
lines generated simultaneously to the lines expressing
NM23-H1 mutants were utilized as standards. Each
mutant was tested for its e¡ect on IKACh, using the
protocols described above.
Again, desensitization of IKACh was found to be
the only property of expressed muscarinic K chan-
nels that was substantially a¡ected by mutations in
NM23-H1. As shown in Fig. 4 and summarized in
Fig. 3, in cells carrying NM23-H1P96S the desensiti-
zation of IKACh was minimal, and the time course of
IKACh resembled the pro¢le seen in cells that over-
express wild-type NM23-H1 shown in Fig. 2. Similar
results were obtained with NM23-H1S44A (Fig. 3),
indicating that neither the S44A nor the P96S muta-
tion a¡ects the role of NM23-H1 in desensitization.
In contrast, the decay of IKACh in cells overexpress-
ing NM23-H1S120G was signi¢cantly higher
(P6 1.0U1038) than in cells expressing wild-type
protein (Figs. 3 and 4). The same was true for an-
other mutant of S120, NM23-H1S120A (P6 0.01), in-
dicating that changes in this residue abolish the sup-
pressive e¡ect of NM23-H1 on desensitization. More
importantly, in the two clonal lines expressing
NM23-H1S120G (I108 and I205; Fig. 3) the decline
of muscarinic K currents is substantially enhanced
in comparison to control cells (P6 0.005), suggesting
that the S120G mutation generates a protein with a
prominent negative e¡ect on the muscarinic re-
sponse.
When NM23-H1 mutants were tested for their ef-
fects on the recovery from desensitization, a slightly
di¡erent pattern emerged (Fig. 5). Whereas resensiti-
zation with the S120G mutant was similar to con-
trols and less than with wild type (P6 0.05), the ex-
tent of recovery with the S120A resembled the level
obtained with wild-type protein, indicating that this
mutation is less disruptive for the reversal of desen-
sitization. In cells expressing all other mutants, re-
covery from desensitization was complete, as seen
with wild-type NM23-H1.
4. Discussion
The major ¢ndings of this work are: (a) overex-
pression of NM23-H1 attenuates desensitization of
IKACh, and (b) mutations in one residue of NM23-
H1, serine 120, abolish the suppressive e¡ect of
NM23-H1 on desensitization. Thus, our previous ob-
servation that binding of speci¢c antibodies to
NM23 present in atrial membrane patches decreases
the open probability of native muscarinic K chan-
nels [7] can be now attributed to accelerated desensi-
tization of the muscarinic response. Furthermore, the
sensitivity of desensitization (Fig. 3) and recovery
from desensitization (Fig. 5) to the level of expres-
sion of NM23 and to speci¢c point mutations appear
to be distinct, suggesting that NM23-H1 plays di¡er-
ent roles in the two processes.
The molecular mechanisms underlying acute de-
sensitization of native IKACh are not well de¢ned
[6,60]; similarly, little is known about the steps lead-
ing to resensitization of the response. Thus, whereas
part of the desensitization process seems to re£ect
phosphorylation of the m2 receptor by the receptor
kinase GRK2 [61], some steps take place down-
stream from the receptor, and therefore may a¡ect
the G protein and/or the channel [6,60^62]. Further-
more, free GKi-subunits liberated during muscarinic
receptor activation may also play a role in desensiti-
zation, since reduction of the content of GiK1 in oo-
cytes expressing GIRK1 and m2 receptors sup-
pressed the decay of muscarinic currents [63].
Consequently, at present it is not possible to assign
a speci¢c role to NM23-H1 in these processes. On
the other hand, the results obtained with the point
mutants provide some clues to a possible mechanism
of action of NM23-H1 on this signaling pathway.
The NM23 mutants tested here fall into two
groups, S44A and P96S, which behave similarly to
the wild-type NM23-H1, and the S120 mutants,
which eliminate the ability to suppress desensitiza-
tion. The S44A mutation of serine 44, a site of phos-
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phorylation on NM23-H1 [16], was functionally si-
lent in assays of cell motility as well [48]; the present
results establish that loss of this phosphorylation site
does not a¡ect most biological activities of NM23-
H1. In contrast, P96S and S120G, and to a lesser
degree S120A, abrogate the motility inhibitory activ-
ity of NM23-H1 [48], but only the S120 mutants
eliminate the e¡ect of NM23-H1 on desensitization
of IKACh (Figs. 3 and 4). This discrepancy suggests
that NM23-H1 in£uences cell motility and desensiti-
zation through distinct mechanisms, and indicates
that S120 is crucial for most, if not all, functions
of NM23.
Given that P96S and S120G behave di¡erently in
regard to the muscarinic system, their common fea-
tures are unlikely to account for the e¡ects of S120G
and S120A on the desensitization of muscarinic K
currents. Thus, the decreased stability of P96S or
S120G towards heat and urea denaturation
[37,38,64] and their low phosphorylating activity to-
wards other proteins [21,23] are not likely to be in-
volved in the desensitization of IKACh. An evident
di¡erence between the P96 and S120 mutants is
that the latter substitution eliminates a potential
phosphorylation site in NM23-H1. However, the
quantitative di¡erence in behavior of S120G and
S120A suggests that the presence of a glycine at
this position has unique functional consequences.
The observation of enhanced desensitization rela-
tive to controls in the two lines overexpressing the
S120G mutant indicate that this polypeptide retains
the ability to interact with the muscarinic K chan-
nel pathway, but does so in a negative manner. By
analogy with the stabilizing e¡ect of the S120G mu-
tation on NM23-Mer5 complexes [38], we speculate
that the mutant may bind tightly to an element of the
muscarinic system, in contrast to wild-type NM23-
H1, which would interact with this protein with a
lower a⁄nity. Stable interactions between compo-
nents of a signaling pathway can have deleterious
e¡ects, since signal transduction mechanisms rely
on transient protein-protein interactions that pro-
mote complex formation only during stimulation
and permit disaggregation when the signal ends.
The site of action of NM23-H1 on the muscarinic
pathway is still unclear. Our previous results in atrial
membrane patches demonstrated that participation
of NM23 in the channel activation process requires
activated receptors, and was not detectable in prep-
arations where channel activity was not under tight
receptor control [7]. Although this would seem to
indicate that NM23 alters receptor-Gk coupling di-
rectly, binding of agonists to m2 receptors activates
other signaling cascades as well [65], which may in
turn a¡ect desensitization of IKACh. A recently de-
scribed example of such a mechanism of feedback
regulation is the desensitization of W-opioid receptor
signaling via adenylate cyclase by an independent
e¡ector pathway, in this case the MAP kinase cas-
cade [66]. Thus, NM23 may target the products of
other signal transduction pathways that converge on
the muscarinic K channel system following receptor
activation. Finally, both NM23 and GIRK1 interact
with the cytoskeletal protein vimentin [43,67], an in-
teraction that may underlie channel properties such
as mechano-sensitivity [68] and localization at specif-
ic sites in the membrane [67]. Therefore, NM23-H1
may a¡ect desensitization of IKACh indirectly,
through an e¡ect on cytoskeleton organization.
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